RESEARCHER PROFILE
Gerhard Ehninger
← Back to Technische Universität Dresden
G
Technische Universität Dresden
Gerhard Ehninger works in Acute Myeloid Leukemia Research, Hematopoietic Stem Cell Transplantation, Retinoids in leukemia and cellular processes, Chronic Myeloid Leukemia Treatments, Transplantation: Methods and Outcomes. Recorded institutional associations include University Hospital Carl Gustav Carus, Technische Universität Dresden.
1,205Publications
49,532Citations
104H-index
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
2017 · 2,227 citationsAnalysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
2002 · 1,735 citationsRetinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
2013 · 1,612 citationsMesenchymal Stem Cells Can Be Differentiated Into Endothelial Cells In Vitro
2004 · 1,317 citationsPeripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
2012 · 920 citationsPrevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML)
2006 · 736 citationsAcute myeloid leukaemia
2016 · 592 citationsSorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3 –Internal Tandem Duplication Mutation (SORMAIN)
2020 · 555 citationsDonor Lymphocyte Infusion in the Treatment of First Hematological Relapse After Allogeneic Stem-Cell Transplantation in Adults With Acute Myeloid Leukemia: A Retrospective Risk Factors Analysis and Comparison With Other Strategies by the EBMT Acute Leukemia Working Party
2007 · 516 citationsPhase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
2010 · 500 citationsPolymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation
1995 · 465 citationsAddition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
2015 · 401 citationsAzacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial
2011 · 389 citationsImproved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
2016 · 389 citationsLetermovir for Cytomegalovirus Prophylaxis in Hematopoietic-Cell Transplantation
2014 · 378 citationsRapamycin extends murine lifespan but has limited effects on aging
2013 · 373 citationsIndividual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup
2004 · 356 citationsDistribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
2014 · 355 citationsBCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation
2017 · 351 citationsMeasurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial
2018 · 345 citationsTherapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study
2012 · 341 citationsSorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
2013 · 313 citationsP-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate
2004 · 307 citationsTreatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium
2008 · 306 citationsComplete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes
2010 · 304 citations
